A new double-blind, placebo-controlled trial identifies effective ketamine doses (two subanesthetic dosage levels) for treatment-resistant depression, which were more effective than an active placebo in reducing depression symptoms over a three-day period.

See the source article by following the link below:
A new double-blind, placebo-controlled trial identifies effective ketamine doses (two subanesthetic dosage levels) for treatment-resistant depression, which were more effective than an active placebo in reducing depression symptoms over a three-day period.